Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

579
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
579
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

969
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
969
Hypertension I: Introduction01:28

Hypertension I: Introduction

911
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
911
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

452
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
452
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

4.4K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.4K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

659
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
659

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358].

Critical reviews in oncology/hematology·2026
Same author

Clinical Research Article Surgical Reconstruction of the Proximal Tibia in Primary Bone Tumors in Children and Adolescent Patients: A 30-Year Retrospective Study of Osteoarticular and Resurfaced Allografts.

Journal of pediatric orthopedics·2026
Same author

Circulating IGF2BP3 enables risk stratification and predicts treatment response in Ewing sarcoma.

Scientific reports·2026
Same author

Management of atypical cartilaginous tumors (ACT): an Italian Sarcoma Group (ISG) consensus document.

Critical reviews in oncology/hematology·2026
Same author

Selective Femoral Resurfacing for Bilateral Knee Osteonecrosis: A Bone-Preserving Alternative to Total Knee Arthroplasty.

Case reports in orthopedics·2026
Same author

3D-Printed Cut Guides and Custom Prostheses for Pelvic Reconstruction in Bone Sarcoma Patients: Complications, Survival Rates, and Functional Outcomes.

Orthopaedic surgery·2025
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
Same journal

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
See all related articles

Related Experiment Video

Updated: Feb 7, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

793

Adducin and hypertension.

Jan A Staessen1, Giuseppe Bianchi

  • 1University of Leuven, Study Coordinating Centre, Laboratory of Hypertension, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. jan.staessen@med.kuleuven.be

Pharmacogenomics
|October 7, 2005
PubMed
Summary
This summary is machine-generated.

A specific alpha-adducin gene mutation increases blood pressure by affecting kidney function and interacting with the hormone ouabain. A drug, rostafuroxin, shows promise in treating this form of hypertension.

More Related Videos

A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice
09:03

A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice

Published on: November 15, 2019

10.8K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.7K

Related Experiment Videos

Last Updated: Feb 7, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

793
A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice
09:03

A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice

Published on: November 15, 2019

10.8K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.7K

Area of Science:

  • Biochemistry
  • Nephrology
  • Pharmacology

Background:

  • Adducin is a protein complex involved in cytoskeleton regulation.
  • Mutations in alpha-adducin are linked to hypertension through effects on renal tubular cells.
  • Ouabain, a hormone, modulates sodium-potassium ATPase activity and natriuresis.

Purpose of the Study:

  • To review evidence linking alpha-adducin Gly460Trp polymorphism, ouabain, and hypertension.
  • To explore the pathogenetic mechanisms of hypertension in this context.
  • To highlight the potential of a pharmacogenomic approach for clinical application.

Main Methods:

  • Review of experimental, clinical, and epidemiological studies.
  • Analysis of the interaction between alpha-adducin polymorphism and ouabain levels.
  • Consideration of rostafuroxin's mechanism of action.

Main Results:

  • Alpha-adducin mutations stimulate Na(+), K(+)-ATPase activity, increasing renal sodium reabsorption and blood pressure.
  • Plasma ouabain levels correlate with the presence of mutated alpha-adducin alleles.
  • Rostafuroxin selectively displaces ouabain, lowering blood pressure.

Conclusions:

  • The alpha-adducin Gly460Trp polymorphism and ouabain interaction are key in a specific hypertension pathway.
  • Pharmacogenomic strategies, like using rostafuroxin, are crucial for translating these findings into clinical practice.